Exploration of the Cellular and Molecular Mechanisms in Patients Receiving Biotherapies Targeting the IL-23/IL-17 Axis in Cutaneous Psoriasis
Recruiting
Observational Study
Psoriasis
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 90 (estimated)
- Sponsor
- Institut Pasteur · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This is a research study involving humans, of the interventional type with minimal risks and constraints (RIPH2). It is a monocentric, non randomized prospective study aiming to better understand the mechanisms of the response to anti-IL-23 biologics in psoriasis patients attending the dermatology department of hospital Cochin (APHP).
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
All patients:
* Adults (\>18 years)
* Presenting with cutaneous psoriasis
* Patients have signed an informed consent
* Beneficiary of the health insurance, except for the AME Only for patients of Group 1
* Patients require systemic treatment for psoriasis
* Patients are naïve t…
Contacts